☆ 4.6 Letter

Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)

Get Full Text
Add to Collection

Journal

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 80, Issue 2, Pages 564-566

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2018.08.017

Keywords

-

Categories

Dermatology

Funding

  1. Regeneron
  2. Genentech-Roche
  3. Novartis
  4. National Institutes of Health
  5. Parker Institute for Cancer Immunotherapy
  6. National Science Foundation

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.